ATE386938T1 - Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen - Google Patents

Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Info

Publication number
ATE386938T1
ATE386938T1 AT99950002T AT99950002T ATE386938T1 AT E386938 T1 ATE386938 T1 AT E386938T1 AT 99950002 T AT99950002 T AT 99950002T AT 99950002 T AT99950002 T AT 99950002T AT E386938 T1 ATE386938 T1 AT E386938T1
Authority
AT
Austria
Prior art keywords
cancer
ykl
marker
indicator
predicting cancer
Prior art date
Application number
AT99950002T
Other languages
English (en)
Inventor
Paul Price
Julia Johansen
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE386938T1 publication Critical patent/ATE386938T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
AT99950002T 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen ATE386938T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/164,862 US7229770B1 (en) 1998-10-01 1998-10-01 YKL-40 as a marker and prognostic indicator for cancers

Publications (1)

Publication Number Publication Date
ATE386938T1 true ATE386938T1 (de) 2008-03-15

Family

ID=22596399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950002T ATE386938T1 (de) 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Country Status (8)

Country Link
US (2) US7229770B1 (de)
EP (2) EP1804062A3 (de)
JP (1) JP2002525632A (de)
AT (1) ATE386938T1 (de)
AU (1) AU6275799A (de)
CA (1) CA2343972A1 (de)
DE (1) DE69938187D1 (de)
WO (1) WO2000019206A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3116800A (en) * 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US7214373B2 (en) * 2001-07-24 2007-05-08 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070269831A1 (en) * 2003-09-10 2007-11-22 Sloan-Kettering Institute For Cancer Research Method for Early Detection of Ovarian Cancer
EP1673395A1 (de) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Veränderungen der serum-halbwertszeiten von fc-fusionsprotein durch mutagenese der position 250, 314 und/oder 428 der schweren kette der konstanten region von ig
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP1835027B1 (de) * 2004-12-07 2015-02-25 Toray Industries, Inc. Neues krebsantigenpeptid und dessen verwendung
ATE493439T1 (de) 2005-02-28 2011-01-15 Bio Y As Monoklonale ykl-40-antikörper
US20100196509A1 (en) * 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8409411B2 (en) * 2005-12-02 2013-04-02 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Portland State University Nano-porous membrane based sensors
EP2363205A3 (de) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen Und Verfahren Zur Verwendung Bei Der Bildung Und Kontrolle Von Nanoreaktoren
US20080058432A1 (en) * 2006-03-03 2008-03-06 Yixin Wang Molecular assay to predict recurrence of Duke's B colon cancer
US20110143380A1 (en) * 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530168B1 (de) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
FR2908654B1 (fr) * 2006-11-20 2014-04-04 Oreal Utilisation cosmetique de proteines de type chitinase
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
NZ586746A (en) * 2008-01-23 2012-07-27 Righospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
NZ586909A (en) * 2008-01-23 2012-05-25 Herlev Hospital Ykl-40 as a general marker for non-specific disease
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010028657A1 (en) * 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Ykl-40 as a marker for selection of treatment and monitoring of a disease
US8580520B2 (en) * 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
US20120040354A1 (en) * 2008-09-15 2012-02-16 Julia Sidenius Johansen Methods of classifying the severity of diseases or disorders
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
RU2423707C2 (ru) * 2009-06-30 2011-07-10 Федеральное государственное учреждение науки Казанский научно-исследовательский институт эпидемиологии и микробиологии Роспотребнадзора Способ определения хитиназо-подобного белка ykl-40 в биоптатах и экскретах человека
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
CA2781290A1 (en) 2009-11-20 2011-05-26 Lynn K. Gordon Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
US8198035B2 (en) 2009-11-25 2012-06-12 Siemens Healthcare Diagnostics Inc. Galactose-α-1,3-galactose-macromolecule conjugates and methods employing same
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
US9410968B2 (en) 2011-04-04 2016-08-09 Universiteit Gent Biomarkers for acute kidney injury
US20130035290A1 (en) * 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9575073B2 (en) * 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
RU2623869C1 (ru) * 2016-07-29 2017-06-29 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ прогнозирования безрецидивной выживаемости у больных раком молочной железы
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US12320812B2 (en) * 2019-02-06 2025-06-03 Bpgbio, Inc. Markers for the diagnosis of biochemical recurrence in prostate cancer
JP7356625B2 (ja) * 2019-07-08 2023-10-05 国立大学法人大阪大学 癌患者の予後予測方法、抗癌療法の有効性の予測方法および癌患者に対する適切な療法の選択方法
KR102142499B1 (ko) 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체
WO2022115705A2 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN114569725B (zh) * 2022-03-29 2023-05-12 潍坊医学院 Ykl-40在黑色素瘤治疗中的应用
KR102820652B1 (ko) 2022-05-10 2025-06-16 재단법인 오송첨단의료산업진흥재단 항-키티나제-3-유사 단백질 1 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4828981A (en) * 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
JPS6323898A (ja) 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5773259A (en) 1996-03-20 1998-06-30 Smithkline Beecham Corporation Tissue remodeling proteins
EP0805206A3 (de) 1996-05-03 1999-09-15 Smithkline Beecham Corporation Menschliches Glycoprotein aus Knorpel
WO1998006859A1 (en) 1996-08-09 1998-02-19 Human Genome Sciences, Inc. Human chitinase alpha and chitinase alpha-2
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene
US5726061A (en) * 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
ATE493439T1 (de) 2005-02-28 2011-01-15 Bio Y As Monoklonale ykl-40-antikörper

Also Published As

Publication number Publication date
EP1112497A1 (de) 2001-07-04
WO2000019206A9 (en) 2000-09-08
AU6275799A (en) 2000-04-17
CA2343972A1 (en) 2000-04-06
US7670599B2 (en) 2010-03-02
EP1804062A2 (de) 2007-07-04
US7229770B1 (en) 2007-06-12
DE69938187D1 (de) 2008-04-03
US20050226884A1 (en) 2005-10-13
WO2000019206A1 (en) 2000-04-06
JP2002525632A (ja) 2002-08-13
EP1112497B1 (de) 2008-02-20
EP1804062A3 (de) 2007-07-11

Similar Documents

Publication Publication Date Title
DE69938187D1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE352641T1 (de) Zirkulierendes epstein-barr virus dna im serum der patienten mit gastrischem krebs
ATE337413T1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
ATE331811T1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
DK1109937T3 (da) Fremgangsmåde til diagnosticering , monitorering, stadiebestemmelse og billeddiagnostisk undersögelse for forskellige cancere
ATE424560T1 (de) Marker für neuromyelitis optica
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE522620T1 (de) Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
EP2009115A3 (de) Verfahren und Nukleinsäuren für Analysen von Zellwucher-Störungen
DE602004015626D1 (de) Bei brustkrebs
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2002064015A3 (en) Pin1 as a marker for prostate cancer
BR0314155A (pt) Métodos para diagnosticar câncer cervical
ATE481645T1 (de) Biomarker für den frühzeitigen nachweis von ovarialkarzinom
ATE377192T1 (de) Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties